Join Longboard Pharmaceuticals for a hybrid R&D day with company management and featuring key opinion leaders who will discuss the unmet need and current treatment landscape for patients suffering from Developmental and Epileptic Encephalopathies (DEEs), including:

• Dennis Dlugos, MD, MSCE, pediatric neurologist at Children’s Hospital of Philadelphia, Vice President & Officer of the Epilepsy Study Consortium, and Principal Investigator of Longboard’s Phase 1b/2a PACIFIC Study
• Ilene Penn Miller, JD, LLM, Director, Rare Epilepsy Network (REN)

The event will include updates on global Phase 3 clinical development plans for Longboard’s investigational drug bexicaserin, an oral, centrally acting, 5-HT2C superagonist that received Breakthrough Therapy designation by the FDA for the treatment of seizures associated with DEEs in patients two years of age or older.

A live question and answer session will follow the formal presentations. This event will also be available to virtual attendees via the Company’s website.

Due to space restrictions, please limit the number of attendees per firm.